Imagine trying to give a regular medical treatment to people who are constantly traveling for work and rarely stay in one place. This project tests whether long-acting injections or flexible pill schedules work better than traditional daily meds for these men. It's like finding the most convenient 'subscription plan' for health that fits a nomadic lifestyle.
Traditional HIV prevention fails mobile men who cannot maintain daily pill regimens due to travel. This leads to poor retention in care and higher infection risks in migrant workforces.
An implementation trial and a cost-effectiveness model. It also produced operational tools for service providers to deliver PrEP to mobile populations.
If you are a drug developer dealing with low patient adherence in mobile populations — this project developed evidence on the effectiveness of CAB-LA that helps optimize dosing schedules for 400 men. This allows for better product positioning in the Sub-Saharan market.
If you are a clinic operator dealing with high patient dropout rates among migrant workers — this project developed operational tools for PrEP implementation that improve retention in care. This ensures a more stable and predictable patient revenue stream.
If you are an insurer dealing with high HIV-related costs in mobile workforces — this project developed a cost-effectiveness model using an HIV synthesis model. This helps in predicting long-term savings by switching to long-acting prevention.
Based on available project data, the project is currently using an HIV synthesis model to determine the specific cost and cost-effectiveness of oral versus injectable PrEP.
Based on available project data, the study is designed to provide evidence for guidelines change and operational tools specifically to inform the scalability of PrEP for mobile men.
Based on available project data, there is no mention of specific patents or licensing agreements; the focus is on implementation evidence and operational tools.
The randomized phase completes in May 2025, and the last participant visit is expected in April 2026.
The project assesses the feasibility and fidelity of delivering PrEP in different settings to identify necessary service-level adaptations for providers.
The consortium is research-heavy, consisting of 3 universities and 2 research organizations, with a low industry presence of only 1 company (12% ratio). This suggests the output is primarily evidence-based and operational rather than a commercial product. The coordination by the Desmond Tutu Health Foundation (an NGO/NPC) emphasizes a public health focus over a profit-driven motive.
Contact the Desmond Tutu Health Foundation NPC in South Africa
Contact us to access the operational tools for PrEP implementation in mobile populations.
